NCT05930119View on ClinicalTrials.gov

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

August 28, 2023

Study Completion Date

August 28, 2023

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

HMPL-453

300 mg HMPL-453

DRUG

Rabeprazole

20 mg of rabeprazole will be administered by mouth once daily.

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

Sponsors

Lead Sponsor

Hutchmed
All Listed Sponsors
lead

Hutchmed

INDUSTRY